| Literature DB >> 29423819 |
Jalaluddin M Ashraf1, Mohammad Azam Ansari2, Sana Fatma3, Saleh M S Abdullah4, Johar Iqbal5, Aymen Madkhali4, Al Hassan Hamali4, Saheem Ahmad6, Ahmed Jerah4, Valentina Echeverria7, George E Barreto8, Ghulam Md Ashraf9.
Abstract
Advanced glycation end products (AGEs) are implicated in several central nervous system (CNS) pathologies including Alzheimer and Parkinson's diseases. In the face-off of AGE menace, we have attempted to investigate the zinc oxide nanoparticle (ZnONP) role in inhibition of AGE formation. Synthesized ZnONPs were used to investigate the inhibitory effects on AGE formation. The inhibitory effects of ZnONPs on AGE formation were determined by biophysical immunological and biochemical techniques. The results showed that ZnONP is a potential anti-glycating agent inhibiting AGE formation as well as protecting the protein structure from change. Therefore, our findings suggest ZnONPs may be used as a therapeutic in resolving the AGE role in CNS-related complications.Entities:
Keywords: Advanced glycation end products; Anti-glycating agent; Nanoparticles; Neurodegenerative diseases
Mesh:
Substances:
Year: 2018 PMID: 29423819 DOI: 10.1007/s12035-018-0935-x
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590